Explore more publications!
Tech Channel Mongolia
Got News to Share?

Tech Channel Mongolia: Press Releases

Browse our comprehensive archive of press releases by date.
Select a specific day to access all press releases published on Tech Channel Mongolia.

October 2025

Mo Tu We Th Fr Sa Su
1 2 3 4 5
6 7 8 9 10 11 12
13 14 15 16 17 18 19
20 21 22 23 24 25 26
27 28 29 30 31

November 2025

Mo Tu We Th Fr Sa Su
1 2
3 4 5 6 7 8 9
10 11 12 13 14 15 16
17 18 19 20 21 22 23
24 25 26 27 28 29 30

December 2025

Mo Tu We Th Fr Sa Su
1 2 3 4 5 6 7
8 9 10 11 12 13 14
15 16 17 18 19 20 21
22 23 24 25 26 27 28
29 30 31

Press releases published on December 6, 2025

TScan Therapeutics Announces Positive Updated Data from the ALLOHA™ Phase 1 Heme Trial at the 67th American Society of Hematology Annual Meeting and Exposition
December 6, 2025

TScan Therapeutics Announces Positive Updated Data from the ALLOHA™ Phase 1 Heme Trial at the 67th American Society of Hematology Annual Meeting and Exposition

Indeterminate GlobeNewswire
Fulcrum Therapeutics Announces Positive Initial Results from the 20 mg Dose Cohort of the Phase 1b PIONEER Trial of Pociredir in Sickle Cell Disease at the 67th American Society of Hematology Annual Meeting
December 6, 2025

Fulcrum Therapeutics Announces Positive Initial Results from the 20 mg Dose Cohort of the Phase 1b PIONEER Trial of Pociredir in Sickle Cell Disease at the 67th American Society of Hematology Annual Meeting

Indeterminate GlobeNewswire
Sapu Nano 宣佈由 Deciparticle™ 驅動的生物標記框架，可識別出最有可能對靜脈注射依維莫司納米藥物 Sapu003 產生反應的腫瘤
December 6, 2025

Sapu Nano 宣佈由 Deciparticle™ 驅動的生物標記框架，可識別出最有可能對靜脈注射依維莫司納米藥物 Sapu003 產生反應的腫瘤

Indeterminate GlobeNewswire
BioNTech and OncoC4 Announce Clinically Meaningful Overall Survival Benefit for Selective Treg Modulator Gotistobart in Patients with Previously Treated Squamous Non-Small Cell Lung Cancer
December 6, 2025

BioNTech and OncoC4 Announce Clinically Meaningful Overall Survival Benefit for Selective Treg Modulator Gotistobart in Patients with Previously Treated Squamous Non-Small Cell Lung Cancer

Indeterminate GlobeNewswire
BioNTechs und OncoC4s selektiver Treg-Modulatorkandidat Gotistobart erzielte klinisch relevanten Gesamtüberlebensvorteil bei Patientinnen und Patienten mit zuvor behandeltem Plattenepithelkarzinom der Lunge
December 6, 2025

BioNTechs und OncoC4s selektiver Treg-Modulatorkandidat Gotistobart erzielte klinisch relevanten Gesamtüberlebensvorteil bei Patientinnen und Patienten mit zuvor behandeltem Plattenepithelkarzinom der Lunge

Indeterminate GlobeNewswire
Remedy's Nutrition® Launches Cyst-Be-Gone™ — Advanced Herbal Formula to Support Natural Cyst & Tissue Wellness
December 6, 2025

Remedy's Nutrition® Launches Cyst-Be-Gone™ — Advanced Herbal Formula to Support Natural Cyst & Tissue Wellness

Indeterminate GlobeNewswire
Legend Biotech Highlights New CARVYKTI® Data in Multiple Myeloma and First-in-Human Results from Novel CAR-T Platform in Non-Hodgkin Lymphoma at ASH 2025
December 6, 2025

Legend Biotech Highlights New CARVYKTI® Data in Multiple Myeloma and First-in-Human Results from Novel CAR-T Platform in Non-Hodgkin Lymphoma at ASH 2025

Indeterminate GlobeNewswire
Evaxion presents new data for EVX-04, a cancer vaccine candidate for acute myeloid leukemia at ASH Annual Meeting
December 6, 2025

Evaxion presents new data for EVX-04, a cancer vaccine candidate for acute myeloid leukemia at ASH Annual Meeting

Indeterminate GlobeNewswire
RadiantVibe Capital Consortium Debuts Insight Access Dashboard as Part of Ambrose Wetherby’s Transparency Initiative
December 6, 2025

RadiantVibe Capital Consortium Debuts Insight Access Dashboard as Part of Ambrose Wetherby’s Transparency Initiative

Indeterminate GlobeNewswire
Ascentage Pharma Presents Pivotal China Registrational Study Data for Lisaftoclax in Oral Report at 2025 American Society of Hematology (ASH) Annual Meeting
December 6, 2025

Ascentage Pharma Presents Pivotal China Registrational Study Data for Lisaftoclax in Oral Report at 2025 American Society of Hematology (ASH) Annual Meeting

Indeterminate GlobeNewswire
Nurix Therapeutics Presents New Data Demonstrating Durable, Deepening Responses in Phase 1 Trial of Bexobrutideg (NX-5948) in Patients with Relapsed or Refractory Chronic Lymphocytic Leukemia (CLL) at the 67th American Society of Hematology (ASH)…
December 6, 2025

Nurix Therapeutics Presents New Data Demonstrating Durable, Deepening Responses in Phase 1 Trial of Bexobrutideg (NX-5948) in Patients with Relapsed or Refractory Chronic Lymphocytic Leukemia (CLL) at the 67th American Society of Hematology (ASH)…

Indeterminate GlobeNewswire
Cogent Biosciences Presents Full SUMMIT Results of Bezuclastinib in Patients with NonAdvanced Systemic Mastocytosis (NonAdvSM) at the 67th Annual Meeting of the American Society of Hematology (ASH)
December 6, 2025

Cogent Biosciences Presents Full SUMMIT Results of Bezuclastinib in Patients with NonAdvanced Systemic Mastocytosis (NonAdvSM) at the 67th Annual Meeting of the American Society of Hematology (ASH)

Indeterminate GlobeNewswire
Io Therapeutics presents today at the American Society for Hematology Annual Meeting, preclinical studies demonstrating combination treatment with BCMA CAR-T cells plus the company's RXR agonist compound IRX4204 has synergistic efficacy against human…
December 6, 2025

Io Therapeutics presents today at the American Society for Hematology Annual Meeting, preclinical studies demonstrating combination treatment with BCMA CAR-T cells plus the company's RXR agonist compound IRX4204 has synergistic efficacy against human…

Indeterminate GlobeNewswire
Arvinas Presents Preclinical Data Supporting Mechanistic Synergies and Enhanced Antitumor Activity with the Combination of ARV-393 and Glofitamab at the 2025 American Society of Hematology Annual Meeting and Exposition
December 6, 2025

Arvinas Presents Preclinical Data Supporting Mechanistic Synergies and Enhanced Antitumor Activity with the Combination of ARV-393 and Glofitamab at the 2025 American Society of Hematology Annual Meeting and Exposition

Indeterminate GlobeNewswire
Aptose’s Tuspetinib Triple Drug Therapy Featured at the 2025 ASH Annual Meeting; High Rate of Frontline Clinical Responses Continues Across AML Populations
December 6, 2025

Aptose’s Tuspetinib Triple Drug Therapy Featured at the 2025 ASH Annual Meeting; High Rate of Frontline Clinical Responses Continues Across AML Populations

Indeterminate GlobeNewswire
Beam Therapeutics Reports Updated Data from BEACON Phase 1/2 Trial of ristoglogene autogetemcel (risto-cel) Highlighting Durable, Differentiated Profile in Sickle Cell Disease (SCD) at American Society of Hematology (ASH) Annual Meeting
December 6, 2025

Beam Therapeutics Reports Updated Data from BEACON Phase 1/2 Trial of ristoglogene autogetemcel (risto-cel) Highlighting Durable, Differentiated Profile in Sickle Cell Disease (SCD) at American Society of Hematology (ASH) Annual Meeting

Indeterminate GlobeNewswire
Disc Medicine Presents Positive Initial Data from RALLY-MF Phase 2 Trial in Patients with Myelofibrosis (MF) and Anemia at the 67th American Society of Hematology (ASH) Annual Meeting
December 6, 2025

Disc Medicine Presents Positive Initial Data from RALLY-MF Phase 2 Trial in Patients with Myelofibrosis (MF) and Anemia at the 67th American Society of Hematology (ASH) Annual Meeting

Indeterminate GlobeNewswire
BI DeFi Launches New Daily Yield Plan as Demand for Accessible Crypto Income Solutions Grows
December 6, 2025

BI DeFi Launches New Daily Yield Plan as Demand for Accessible Crypto Income Solutions Grows

Indeterminate GlobeNewswire
Sapu Nano 公布新的药代动力学数据显示，与口服给药相比，静脉注射 Sapu003 可将依维莫司的胃肠道积累量减少 67 倍
December 6, 2025

Sapu Nano 公布新的药代动力学数据显示，与口服给药相比，静脉注射 Sapu003 可将依维莫司的胃肠道积累量减少 67 倍

Indeterminate GlobeNewswire
Sapu Nano 發表最新藥物動力學數據，顯示與口服劑量相比，靜脈注射 Sapu003 可將積聚在腸胃的依維莫司 (Everolimus) 量降低達 67 倍
December 6, 2025

Sapu Nano 發表最新藥物動力學數據，顯示與口服劑量相比，靜脈注射 Sapu003 可將積聚在腸胃的依維莫司 (Everolimus) 量降低達 67 倍

Indeterminate GlobeNewswire
Show More

Share us

on your social networks:
Facebook Facebook LinkedIn LinkedIn
AGPs

Get the latest news on this topic.

SIGN UP FOR FREE TODAY

No Thanks

By signing to this email alert, you
agree to our Terms & Conditions